Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859898 · ClinicalTrials.gov registry record · Phase 3
Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,093
- Enrollment target
NCT00859898 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 1,093 participants.
The verdict
NCT00859898, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,093 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with Dapagliflozin monotherapy, after 24 weeks of oral administration of double-blind treatment. The safety of treatment with dapagliflozin will also be assessed in this study
Interventions
- DRUG Dapagliflozin
- DRUG Metformin XR
- DRUG dapagliflozin matching Placebo
- DRUG metformin HCl Modified Release matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,093 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00859898
The ClinicalTrials.gov registry entry for NCT00859898 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,093 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dapagliflozin is the first listed.
NCT00859898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00859898 about?
NCT00859898 is a clinical study titled "Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes". The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with Dapagliflozin monotherapy, after 24 weeks of oral administration of double-blind t...
What is the current status of trial NCT00859898?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,093 participants. The study started on 2009-04. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00859898?
The interventions under investigation include: Dapagliflozin (DRUG), Metformin XR (DRUG), dapagliflozin matching Placebo (DRUG), metformin HCl Modified Release matching Placebo (DRUG).
Who is sponsoring clinical trial NCT00859898?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.